The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).
نویسندگان
چکیده
Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance of optimizing the use of these agents, a multidisciplinary team approach is highly recommended.
منابع مشابه
A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...
متن کاملA Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...
متن کاملCUA - CUOG guidelines for the management of castration - resistant prostate cancer ( CRPC ) : 2013 update cUa gUiD lines
It is suggested to screen for bone metastases with bone scans and monitor for lymph node and visceral metastases/progression with imaging of the abdomen and chest. Patients with a rapid PSA doubling time (PSADT) (<8 months) are at risk for developing earlier metastases. Imaging in these patients should be performed every 3 to 6 months. Patients with slower PSA DT (>12 months) should be screened...
متن کاملCUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update.
It is suggested to screen for bone metastases with bone scans and monitor for lymph node and visceral metastases/progression with imaging of the abdomen and chest. Patients with a rapid PSA doubling time (PSADT) (<8 months) are at risk for developing earlier metastases. Imaging in these patients should be performed every 3 to 6 months. Patients with slower PSA DT (>12 months) should be screened...
متن کاملSingle Orbital Metastasis in Castration-Resistant Prostate Cancer
Introduction: Orbital metastasis of prostate cancer (PC) is very rare and even more unique in castration-resistant PC (CRPC). In this scenario, choline positron emission tomography/computed tomography (choline PET/CT) is the gold-standard restaging method of choice available in our setting, and new anti-androgens treatments show improvement in overall survival. Case presentation: We report the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Canadian Urological Association journal = Journal de l'Association des urologues du Canada
دوره 9 3-4 شماره
صفحات -
تاریخ انتشار 2015